With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
June 15, 2017. We’ve got a nasal spray for that. The FDA has approved desmopressin for nocturia earning some sharp criticism in JAMA last week. If you treat prostate cancer, you have to address nocturia. And desmopressin may give you an additional option. But don’t spray away those nighttime bathroom visits just yet. Desmopressin comes with a serious risk of hyponatremia. So what’s worse for patients: nocturia or Noctiva? For now, the FDA has left that decision in our hands...and our patients' noses.